Vanguards of Health Care: Maraganore on RNAi Long Arc, AI Impact
“I suspect that RNAi-based medicines will approach, rival, maybe even exceed what we’ve seen with monoclonal antibodies historically,” says John Maraganore, the CEO of JMM Innovations and founding CEO of...
By Inigo Imaz Blanco · Bloomberg
“I suspect that RNAi-based medicines will approach, rival, maybe even exceed what we’ve seen with monoclonal antibodies historically,” says John Maraganore, the CEO of JMM Innovations and founding CEO of Alnylam. He joins Bloomberg Intelligence’s senior pharmaceutical analyst Sam Fazeli to reflect on RNAi’s journey from scientific curiosity to a durable drug platform. Maraganore explains Alnylam’s reliance on big pharma partnerships for relatively non-dilutive capital, why rare diseases were the